Price Strategy & Regulation

In Canada, the Patented Medicine Prices Review Board (PMPRB), an independent quasi-judicial tribunal, regulates patented drug prices. The role of this organization to is to protect Canadian consumers from excessively priced patented medicines and to contribute to informed decisions and policy-making by reporting on pharmaceutical and R&D trends.

Under the Regulations put forward by the PMPRB, manufacturers of patented medicines are required to submit information including:

•  Introductory prices
•  Sales of new patented medicines within 60 days of the date of first sale
•  Prices and sales of each patented drug for the first and last six-month period of each year for as long as the drug remains patented.

A detailed knowledge of the PMPPRB Regulations is essential for the effective planning and forecasting of drug prices. The Brogan Inc. team has the expertise and thorough understanding of the PMPRB procedures and regulations to assist drug manufacturers. With over 15 years of liaison experience with the PMPRB and involvement with many complex cases brought to the Board over that time period, Brogan Inc. price regulation consultants are the most trusted advocates to:

•  Develop strategies to protect your investments
•  Provide strategic assessments with detailing all options
•  Make reliable projections based on available options

Our Price Regulation offerings and solutions include:

•  Pricing Strategy for New Patented Drugs
•  Pricing Analysis for Existing Patented Drugs
•  Advisory Assistance or Advanced Ruling Certificate
[Submissions to PMPRB]
•  Data Filing
•  Training Seminars